Here's a smattering of articles recapping comments by Roche CEO Severin Schwan with regard to his company's plans to compete against biosimilars as some of Roche's big biologic drugs start hitting patent expiration dates in next several years.
From the WSJ Health blog, Fierce Biotech, and the regular online WSJ. The Roche counterattack plan has three pillars:
- Developing biobetters of existing Roche drugs
- Continuing to develop new innovative products
- Working with lawmakers/regulators to set bar high for copycat biologics
In other words, Roche will continue to compete in a manner focused on its core strengths and will not try to diversify into generics and biosimilars per se as many of its rivals have stated as their intention.
Posted by Bruce Lehr November 1st 2010.
Comments